Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

SecurityTKAI / Tokai Pharmaceuticals, Inc. (67011N105)
President and CEOMorrison Jodie Pope
IndustryPharmaceutical Preparations
Institutional Owners17
Institutional Shares3,845,578 - 40.81%
Common Shares Outstanding9,422,143 shares (as of 2018-06-30)
Institutional Value$ 24,044,000 USD
Related NVUS / Novus Therapeutics, Inc.

Institutional Stock Ownership and Shareholders()

TKAI / Tokai Pharmaceuticals, Inc. Institutional Ownership

Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) has 17 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,845,578 shares. Largest shareholders include Orbimed Advisors Llc, Lyon Street Capital, LLC, Boxer Capital, LLC, Rtw Investments, Llc, Renaissance Technologies LLC, Vanguard Group Inc, Deutsche Bank Ag\, Derby & Company, Inc, BlackRock Inc., and Pioneer Investment Management Inc.
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-13 13F-HR Renaissance Technologies LLC 109,876 554
2018-08-14 13F-HR VANGUARD GROUP INC 43,911 78,149 77.97 212 547 158.02
2018-05-15 13F-HR ORBIMED ADVISORS LLC 2,537,110 2,537,110 0.00 10,301 12,787 24.13
2018-05-15 13F-HR Lyon Street Capital, LLC 338,929 338,929 0.00 1,376 1,708 24.13
2018-08-13 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 13,377 0 -100.00 67 0 -100.00
2018-05-14 13F-HR DRW Securities, LLC 12,489 15,489 24.02 51 78 52.94
2018-08-14 13F-HR BARCLAYS PLC 20 2 -90.00 0 0
2018-07-24 13F-HR MEEDER ASSET MANAGEMENT INC 755 534 -29.27 4 3,738 93,350.00
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,515 294 -80.59 6 1 -83.33
2018-08-14 13F-HR DEUTSCHE BANK AG\ 4 43,900 1,097,400.00 0 307
2018-08-14 13F-HR RTW INVESTMENTS, LLC 300,000 301,799 0.60 1,512 2,113 39.75
2018-08-14 13F-HR UBS Group AG 2,547 0 -100.00 13 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 0 68 0 0
2018-08-09 13F-HR BlackRock Inc. 15,753 20,417 29.61 80 143 78.75
2018-05-15 13F-HR Boxer Capital, LLC 324,383 1,635
2018-05-21 13F-HR Derby & Company, Inc 18,434 29,545 60.27 75 149 98.67
2018-05-15 13F-HR D. E. Shaw & Co., Inc. 15,679 14,879 -5.10 61 72 18.03

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 67011N105